Khanh Do1, Geraldine O'Sullivan Coyne2, Alice P. Chen2 . The Cancer Therapy Evaluation Program (CTEP) of the NCI assisted in the coordination and Institute; SD, stable disease; RECIST, Response Evaluation Criteria in Solid Tumors. Alice.P. Chen. Head, Early Clinical Trials Development Division of Cancer Treatment and Diagnosis National Cancer Institute. Dr. Chen is the head of the Early 13 Feb 2017 Principal Investigator: Alice Chen. NCI. DCTD. 301.435.0517 Pamela Harris, MD. Study Sponsor: CTEP. NCI Supplied Agent: Ganetespib .. General Concomitant Medication and Supportive Care Guidelines .28. 13 Aug 2018 I am a senior clinical advisor on NCI Phase I Clinical Trials, and am a liaison time at CTEP, I brought into CTEP several agents for development, Terminology Criteria Adverse Events (CTCAE) v4 and am the lead for the 14 Sep 2018 Alice Chen, MD, has wide-ranging experience in medical oncology and MPH, joined the NCI Cancer Therapy Evaluation Program (CTEP) in 6 Jan 2014 Dr. Chen is currently a Medical Officer in the Target Therapeutics 1 Section of the Investigational Drug Branch of the Cancer Therapy Evaluation Program of the National Cancer Institute. Dr. Chen is also the CTEP contact for revision 4 of the Common Terminology Criteria for Adverse Events. Alice Chen, M.D., CTEP NCI developed the original Common Toxicity Criteria (CTC) in 1983 to aid in the >Supply guidelines for protocol parameters:. 23 Jul 2015 Alice Chen, MD, FACP Investigational Drug Branch, CTEP, DCTD National Cancer . Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a underserved in clinical trials Edward L. Trimble, MD, MPH CTEP, DCTD, NCI.CTCAE = Common Terminology Criteria for Adverse Events; MedDRA Division of Cancer Prevention (DCP), Cancer Therapy Evaluation Program (CTEP), and